Ultragenyx Pharmaceutical (NASDAQ:RARE) has expanded its leadership team with the appointment of Wladimir (Vlad) Hogenhuis, M.D., as Chief Operating Officer (COO), effective September 28. Dr. Hogenhuis will report to Emil D. Kakkis, Chief Executive Officer, and will serve on the Executive Leadership Team.
Dr. Hogenhuis joins Ultragenyx from GlaxoSmithKline, where he most recently served as Senior VP and General Manager, Specialty Franchise.
(c) NNA 2018 LEBANON Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers